Verastem, Inc. (NASDAQ:VSTM - Get Free Report) has been assigned a consensus rating of "Buy" from the nine analysts that are currently covering the stock, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have covered the stock in the last year is $13.63.
A number of analysts have commented on the company. Mizuho lifted their price target on Verastem from $7.00 to $9.00 and gave the stock an "outperform" rating in a research report on Thursday, December 19th. Royal Bank of Canada lifted their price target on Verastem from $13.00 to $16.00 and gave the stock an "outperform" rating in a research report on Tuesday, January 7th. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Verastem in a research report on Thursday, December 19th. B. Riley lifted their price target on Verastem from $7.00 to $9.00 and gave the stock a "buy" rating in a research report on Friday, January 31st. Finally, StockNews.com cut Verastem from a "hold" rating to a "sell" rating in a research report on Tuesday, November 19th.
Check Out Our Latest Report on VSTM
Insider Activity at Verastem
In related news, CEO Dan Paterson sold 8,568 shares of Verastem stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $5.24, for a total value of $44,896.32. Following the completion of the transaction, the chief executive officer now owns 347,581 shares in the company, valued at $1,821,324.44. The trade was a 2.41 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 10,367 shares of company stock worth $53,990 in the last 90 days. Corporate insiders own 2.20% of the company's stock.
Hedge Funds Weigh In On Verastem
Institutional investors and hedge funds have recently modified their holdings of the business. Walleye Capital LLC increased its stake in shares of Verastem by 493.7% in the 3rd quarter. Walleye Capital LLC now owns 216,126 shares of the biopharmaceutical company's stock valued at $646,000 after purchasing an additional 179,725 shares in the last quarter. Geode Capital Management LLC increased its stake in Verastem by 67.6% during the 3rd quarter. Geode Capital Management LLC now owns 890,599 shares of the biopharmaceutical company's stock worth $2,663,000 after buying an additional 359,060 shares in the last quarter. Barclays PLC increased its stake in Verastem by 546.7% during the 3rd quarter. Barclays PLC now owns 55,708 shares of the biopharmaceutical company's stock worth $167,000 after buying an additional 47,094 shares in the last quarter. XTX Topco Ltd purchased a new stake in Verastem during the 3rd quarter worth approximately $112,000. Finally, SG Americas Securities LLC purchased a new stake in Verastem during the 3rd quarter worth approximately $43,000. Hedge funds and other institutional investors own 88.37% of the company's stock.
Verastem Stock Down 0.7 %
Verastem stock opened at $5.41 on Friday. The company has a debt-to-equity ratio of 2.77, a current ratio of 3.23 and a quick ratio of 3.23. The stock has a market capitalization of $240.78 million, a price-to-earnings ratio of -1.70 and a beta of 0.28. Verastem has a 1-year low of $2.10 and a 1-year high of $13.82. The business has a fifty day moving average price of $5.49 and a 200-day moving average price of $4.13.
Verastem Company Profile
(
Get Free ReportVerastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Further Reading
Before you consider Verastem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verastem wasn't on the list.
While Verastem currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
